BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 19475451)

  • 1. Incidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C.
    Lambert LA; Armstrong TS; Lee JJ; Liu S; Katz MH; Eng C; Wolff RA; Tortorice ML; Tansey P; Gonzalez-Moreno S; Lambert DH; Mansfield PF
    Ann Surg Oncol; 2009 Aug; 16(8):2181-7. PubMed ID: 19475451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitomycin C Pharmacokinetics as Predictor of Severe Neutropenia in Hyperthermic Intraperitoneal Therapy.
    Kemmel V; Mercoli HA; Meyer N; Brumaru D; Romain B; Lessinger JM; Brigand C
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S873-9. PubMed ID: 26100819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conflicting Data on the Incidence of Leukopenia and Neutropenia After Heated Intraperitoneal Chemotherapy with Mitomycin C.
    Feferman Y; Bhagwandin S; Kim J; Aycart SN; Feingold D; Labow DM; Sarpel U
    Ann Surg Oncol; 2017 Dec; 24(13):3831-3836. PubMed ID: 29027153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of leukopenia and thrombocytopenia with cisplatin plus mitomycin-c versus melphalan in patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Hakeam HA; Arab A; Azzam A; Alyahya Z; Eldali AM; Amin T
    Cancer Chemother Pharmacol; 2018 Apr; 81(4):697-704. PubMed ID: 29429054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Morbidity associated with the use of oxaliplatin versus mitomycin C in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal or appendiceal origin: a multi-institutional comparative study.
    Benzaquen E; Wang Y; Wiseman S; Rosenfeld V; Sideris L; Dubé P; Pelletier JS; Vanounou T
    Can J Surg; 2021 Mar; 64(2):E111-E118. PubMed ID: 33651573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC.
    van Eden WJ; Kok NFM; Woensdregt K; Huitema ADR; Boot H; Aalbers AGJ
    Eur J Surg Oncol; 2018 Feb; 44(2):220-227. PubMed ID: 29258720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repeated cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from appendiceal cancer: analysis of survival outcomes.
    Sardi A; Jimenez WA; Nieroda C; Sittig M; Macdonald R; Gushchin V
    Eur J Surg Oncol; 2013 Nov; 39(11):1207-13. PubMed ID: 24007834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of hematologic toxicity profiles after heated intraperitoneal chemotherapy with oxaliplatin and mitomycin C.
    Votanopoulos K; Ihemelandu C; Shen P; Stewart J; Russell G; Levine EA
    J Surg Res; 2013 Jan; 179(1):e133-9. PubMed ID: 22480844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Mitomycin-C-Induced Neutropenia after Hyperthermic Intraperitoneal Chemotherapy with Cytoreductive Surgery in Colorectal Cancer Patients with Peritoneal Carcinomatosis.
    Lee SJ; Jeon Y; Lee HW; Kang J; Baik SH; Park EJ
    Ann Surg Oncol; 2022 Mar; 29(3):2077-2086. PubMed ID: 34665362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery.
    Prada-Villaverde A; Esquivel J; Lowy AM; Markman M; Chua T; Pelz J; Baratti D; Baumgartner JM; Berri R; Bretcha-Boix P; Deraco M; Flores-Ayala G; Glehen O; Gomez-Portilla A; González-Moreno S; Goodman M; Halkia E; Kusamura S; Moller M; Passot G; Pocard M; Salti G; Sardi A; Senthil M; Spiliotis J; Torres-Melero J; Turaga K; Trout R
    J Surg Oncol; 2014 Dec; 110(7):779-85. PubMed ID: 25088304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylactic hyperthermic intraperitoneal chemotherapy in patients with epithelial appendiceal neoplasms.
    Tuvin D; Berger Y; Aycart SN; Shtilbans T; Hiotis S; Labow DM; Sarpel U
    Int J Hyperthermia; 2016 May; 32(3):311-5. PubMed ID: 27050712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
    Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
    [No Abstract]   [Full Text] [Related]  

  • 13. Toxicity profile of chemotherapy agents used in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies.
    Somashekhar SP; Yethadka R; Kumar C R; Ashwin KR; Zaveri S; Rauthan A
    Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):577-581. PubMed ID: 31677939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pseudomyxoma peritonei of appendiceal origin: result of a single centre study.
    Di Leo A; Corvasce A; Weindelmayer J; Mason EJ; Casella F; de Manzoni G
    Updates Surg; 2020 Dec; 72(4):1207-1212. PubMed ID: 32410159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: the Danish experience.
    Iversen LH; Rasmussen PC; Hagemann-Madsen R; Laurberg S
    Colorectal Dis; 2013 Jul; 15(7):e365-72. PubMed ID: 23458368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes in Peritoneal Carcinomatosis from Appendiceal Goblet Cell Carcinoma Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
    Zambrano-Vera K; Sardi A; Munoz-Zuluaga C; Studeman K; Nieroda C; Sittig M; King MC; Sipok A; Gushchin V
    Ann Surg Oncol; 2020 Jan; 27(1):179-187. PubMed ID: 31646450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulmonary toxicity after intraperitoneal mitomycin C: a case report of a rare complication of HIPEC.
    Abel ML; Kokosis G; Blazer DG
    World J Surg Oncol; 2017 Feb; 15(1):49. PubMed ID: 28219391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes from cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal epithelial neoplasms.
    Narasimhan V; Pham T; Warrier S; Craig Lynch A; Michael M; Tie J; Ramsay R; Heriot A
    ANZ J Surg; 2019 Sep; 89(9):1035-1040. PubMed ID: 30685879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
    Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health-Related Quality of Life After Cytoreductive Surgery/HIPEC for Mucinous Appendiceal Cancer: Results of a Multicenter Randomized Trial Comparing Oxaliplatin and Mitomycin.
    Moaven O; Votanopoulos KI; Shen P; Mansfield P; Bartlett DL; Russell G; McQuellon R; Stewart JH; Levine EA
    Ann Surg Oncol; 2020 Mar; 27(3):772-780. PubMed ID: 31720933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.